Benevolent News Hub

BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.

BenevolentAI’s CTO, Daniel Neil, discusses the approaches we use to fuel continuous innovation in order to unlock new opportunities and future growth.

As VP of AI, Dr Nicola Richmond will be responsible for spearheading BenevolentAI’s AI strategy and working to ensure the Company maintains its leading position in AI-enabled drug discovery.

BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.

BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.

AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.

The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.

BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.

Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.

BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.